PMID- 20626402
OWN - NLM
STAT- MEDLINE
DCOM- 20120703
LR  - 20151119
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 30
IP  - 2
DP  - 2012 Apr
TI  - Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to 
      rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes 
      mellitus inadequately controlled despite prior statin monotherapy.
PG  - 61-74
LID - 10.1111/j.1755-5922.2010.00181.x [doi]
AB  - AIMS: This post hoc analysis compared the effects of switching to 
      ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in 
      uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes 
      mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high 
      risk for coronary vascular disease with elevated LDL-C >/=100 and </=190 mg/dL 
      despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or 
      ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on >/=1 of 
      the following: diagnosis of T2DM, antidiabetic medication, or FPG >/=126 mg/dL. 
      This analysis evaluated percent changes from baseline in lipids among patients 
      with (n = 182) and without T2DM (n = 434). RESULTS: EZE/SIMVA was more effective 
      than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study 
      population and within both subgroups. Numerically, greater between-treatment 
      reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM 
      versus those without T2DM. A significant interaction (P= 0.015) was seen for 
      LDL-C indicating that patients with T2DM achieved larger between-group reductions 
      versus those without T2DM. CONCLUSIONS: Switching to EZE/SIMVA 10/20 mg versus 
      ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - Vaverkova, Helena
AU  - Vaverkova H
AD  - 3rd Department of Internal Medicine, Medical Faculty and University Hospital 
      Olomouc, Olomouc, Czech Republic. helena.vaverkova@fnol.cz
FAU - Farnier, Michel
AU  - Farnier M
FAU - Averna, Maurizio
AU  - Averna M
FAU - Missault, Luc
AU  - Missault L
FAU - Viigimaa, Margus
AU  - Viigimaa M
FAU - Dong, Qian
AU  - Dong Q
FAU - Shah, Arvind
AU  - Shah A
FAU - Johnson-Levonas, Amy O
AU  - Johnson-Levonas AO
FAU - Brudi, Philippe
AU  - Brudi P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100707
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Azetidines)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - AGG2FN16EV (Simvastatin)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Anticholesteremic Agents/adverse effects/*therapeutic use
MH  - Apolipoproteins B/metabolism
MH  - Azetidines/adverse effects/*therapeutic use
MH  - C-Reactive Protein/metabolism
MH  - Cholesterol/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Double-Blind Method
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Ezetimibe
MH  - Fluorobenzenes/adverse effects/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Hypercholesterolemia/blood/*drug therapy
MH  - Lipids/blood
MH  - Odds Ratio
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Rosuvastatin Calcium
MH  - Simvastatin/adverse effects/*therapeutic use
MH  - Sulfonamides/adverse effects/*therapeutic use
EDAT- 2010/07/16 06:00
MHDA- 2012/07/04 06:00
CRDT- 2010/07/15 06:00
PHST- 2010/07/15 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2012/07/04 06:00 [medline]
AID - CDR181 [pii]
AID - 10.1111/j.1755-5922.2010.00181.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2012 Apr;30(2):61-74. doi: 10.1111/j.1755-5922.2010.00181.x. 
      Epub 2010 Jul 7.